- ►diabetesjournals.org J Rosenstock, WT Cefalu, PA Hollander, A … - Diabetes care, 2008 - Am Diabetes Assoc RESULTS—Small differences in FEV 1 favoring subcutaneous insulin developed during the
first 3 months but did not progress. Adjusted treatment group differences in FEV 1 annual rate
of change were −0.007 l/year (90% CI −0.021 to 0.006) between months 0 and 24 and ... Cited by 6 - Related articles - All 10 versions
[CITATION] de la, Pena A, Tibaldi, FS, et al. AIR inhaled insulin in subjects with chronic …
AH Petersen, G Köhler, S Korsatko, A Wutte, M … - Diabetes Care, 2007 - Am Diabetes Assoc RESULTS—Exercise changed the shape of the free plasma insulin curves, but compared with
the NOEX group the area under the curve for free plasma insulin (AUC ins ) for the first 2 h after
the start of exercise was unchanged for EX30 and EX240, while it was 15% decreased for ... Cited by 3 - Related articles - BL Direct - All 5 versions
CK Sreeja, E Samuel, C Kesavachandran, S … - Indian journal of …, 2003 - ncbi.nlm.nih.gov The present study was carried out to assess the lung functions in oral medicated and insulin
administered patients with normal controls. 20 subjects were selected as the study group for
oral medication (Group I), 20 subjects were selected as the study group for insulin ... Cited by 4 - Related articles - BL Direct
C Mathieu, R Cuddihy, RF Arakaki, RM Belin, … - Diabetes Technology …, 2009 - liebertonline.com Abstract Background: Insulin initiation and optimization is a challenge for patients with type 2
diabetes. Our objective was to determine whether safety and efficacy of AIRÒ inhaled insulin
(Eli Lilly and Co., Indianapolis, IN) (AIR is a registered trademark of Alkermes, Inc., ... Cited by 4 - Related articles - All 3 versions
AL Comulada, E Renard, M Nakano, N Rais, … - Diabetes Technology …, 2009 - liebertonline.com Abstract Background: Patients with type 1 diabetes may prefer features of AIRÒ inhaled insulin
(developed by Alkermes, Inc. [Cambridge, MA] and Eli Lilly and Company [Indianapolis, IN]; AIR
is a registered trademark of Alkermes, Inc.) over insulin injection, but the two methods ... Cited by 5 - Related articles - All 3 versions
SK Garg, C Mathieu, N Rais, H Gao, JA … - Diabetes technology & …, 2009 - liebertonline.com Abstract Background: Patients with type 1 diabetes require intensive insulin therapy for optimal
glycemic control. AIRÒ inhaled insulin (system from Eli Lilly and Company, Indianapolis, IN)
(AIR is a registered trademark of Alkermes, Inc., Cambridge, MA) may be an efficacious ... Cited by 5 - Related articles - All 4 versions
[CITATION] Last literature review for version 16.3: Wed Oct 01 00: 00: 00 GMT 2008| This topic …
